Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients

Christine Robin; François Hémery; Christel Dindorf; Julien Thillard; Ludovic Cabanne; Rabah Redjoul; Florence Beckerich; Christophe Rodriguez; Cécile Pautas; Andrea Toma; Sébastien Maury; Isabelle Durand-Zaleski; Catherine Cordonnier

doi:10.1186/s12879-017-2854-2

BMC Infectious Diseases

Table 1 Patient characteristics and bivariate analysis of the costs of the first 12 months after allogeneic stem cell transplantation

From: Economic burden of preemptive treatment of CMV infection after allogeneic stem cell transplantation: a retrospective study of 208 consecutive patients

Variable	Characteristics	Cost after 12 months (€)
Variable	Characteristics	N	Mean (SD)	P-value
Age (years)	< 30	31	103,146 (44,270)	0.6285^a
	30 to 50	65	107,689 (35,434)
	> 50	112	102,125 (36,422)
Sex	F	87	99,375 (33,651)	0.1282^b
Sex	M	121	107,353 (39,485)	0.1282^b
Underlying disease	Acute leukemia and myelodysplastic syndrome	143	100,960 (31,157)	0.2259^a
	Lymphoproliferative disorder	46	111,367 (48,575)
	Myeloproliferative disorder	12	116,491 (56,018)
	Other	7	96,756 (22,709)
Donor type	HLA identical sibling	83	103,795 (41,940)	0.8294^a
	Unrelated donor	107	104,998 (33,467)
	Cord blood unit	18	99,200 (37,742)
D/R match	HLA identical sibling	83	103,795 (41,940)	0.8986^a
	Unrelated donor 10/10 and cord blood unit 6/6	63	102,644 (32,594)
	Unrelated donor 9/10 and cord blood unit 4/6 or 5/6	62	105,706 (35,598)
Stem cell source	Bone marrow	50	99,679 (39,183)	0.7950^a
	Peripheral blood stem cell	140	106,184 (36,604)
	Cord blood unit	18	99,200 (37,742)
Conditioning regimen	Reduced intensity	92	108,178 (31,779)	0.3566^a
	Mini	61	101,129 (42,830)
	Myeloablative	55	100,256 (39,172)
Recipient CMV serology	R+	130	103,494 (34,279)	0.7950^b
Recipient CMV serology	R-	78	104,886 (42,030)	0.7950^b
Number of CMV episodes	0	138	99,793 (39,654)	0.0214^a
	1	44	104,815 (24,271)
	≥2	26	125,080 (36,290)
Acute graft-versus-host disease	0 and 1	112	96,278 (37,441)	0.0011^a
Acute graft-versus-host disease	2 to 4	96	113,043 (35,180)	0.0011^a
Chronic graft-versus-host disease	No	140	101,858 (33,633)	0.2320^b
Chronic graft-versus-host disease	Yes	68	108,458 (43,789)	0.2320^b
Alive at the end of the mentioned period	No	80	109,067 (29,356)	0.1227^b
Alive at the end of the mentioned period	Yes	128	100,859 (41,270)	0.1227^b
First CMV infection	≤100 days	53	109,015 (30,231)	0.1841 ^b
First CMV infection	>100 days	18	119,834 (32,142)	0.1841 ^b

^aAnova test; ^b Student test

Back to article page